Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of PF-00610355 in moderate asthma
2008-007183-42Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-00610355 in asthma (4 arms), sponsored by Pfizer. Primary endpoint: Change from baseline trough FEV1 at week 4. Started Jan 2009; status: terminated.
02
Drugs
PF-00610355
03
Conditions
asthma
Beyond the preview
Go deeper on 2008-007183-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007183-42.